Related Experiment Video
Updated: Jul 9, 2025
09:40
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
5.7K
Imeglimin: the New Kid on the Block
Sandeep Chandra Shrestha1, Setu Gupta2
1Diabetes and Thyroid Center Nepal, Lalitpur, Nepal.
Current Diabetes Reports
|December 5, 2023
Summary
Imeglimin, a novel oral anti-diabetic drug, offers a unique dual mechanism to manage diabetes by enhancing insulin secretion and improving insulin sensitivity. Clinical trials show modest HbA1c reduction and a favorable safety profile.
Area of Science:
- Pharmacology
- Endocrinology
- Mitochondrial Biology
Background:
- Imeglimin represents a new class of oral anti-diabetic agents called "glimins."
- It is approved in Japan, China, and India for managing type 2 diabetes.
- The drug targets mitochondrial dysfunction, a key factor in diabetes pathophysiology.
Purpose of the Study:
- To review and consolidate available data on imeglimin.
- To evaluate imeglimin as a therapeutic option for diabetes management.
- To highlight its unique mechanism of action and clinical efficacy.
Main Methods:
- Review of data from phase III clinical trials.
- Analysis of imeglimin's pharmacological profile and mechanism of action.
- Assessment of its safety and efficacy in diabetes management.
Main Results:
- Imeglimin demonstrates a unique dual action: enhancing glucose-stimulated insulin secretion and improving insulin sensitivity.
- It effectively lowers HbA1c levels with modest reductions.
- The drug exhibits a favorable safety profile, suitable for monotherapy or combination treatment.
Conclusions:
- Imeglimin is a promising new oral anti-diabetic drug with a novel mechanism targeting mitochondrial dysfunction.
- Its efficacy in lowering glucose levels and improving pancreatic function supports its role in diabetes management.
- The recommended dosage is 1000 mg twice daily.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329
01:06Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
01:23Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
01:28Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
01:19Management of Insomnia
257
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
257
01:27Open Angle Glaucoma: Treatment
456
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
456